Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04234152
Other study ID # 2020-2713
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 23, 2020
Est. completion date January 17, 2022

Study information

Verified date October 2022
Source St. Justine's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine if a new and simple method involving complete photo-protection of multivitamins only (since sampling through infusion) will result in a significant reduction of peroxide contamination of parenteral nutrition compared to standard method of parenteral nutrition preparation and infusion in extremely preterm infants.


Description:

Hypothesis and Objectives: The investigators propose, in this pilot study, a new and simple method involving complete photo-protection of multivitamins (MV) only (since sampling through infusion) and they hypothesize that this method will be readily applicable and will result in a significant reduction of peroxide contamination of parenteral nutrition (PN) compared to standard care of PN preparation and infusion method. In Vitro Results Using This Proposed Photo-Protection Method: This method has reduced the quantity of infused peroxides (as equivalent H2O2). When adding the generated peroxides over 5 hours (5 samples: at times 0, 30 minutes, 1, 3 and 5 hours), the total peroxides were 1270± 47 micromolar (μM) without photo-protection vs. 710±16 μM with this method, leading to 45% reduction of peroxides (data presented as a poster presentation in the Pediatric academic societies meeting , 2018, Poster number 2874.625). This reduction is comparable to the previously reported in vitro data for the whole PN complete photo-protection that reported 50% reduction of peroxides. Specific objective of this pilot study: To examine if this new and simple method will be feasible in clinical practice and will result in a significant reduction of urinary peroxide concentration when compared to standard PN compounding and infusion technique. Innovation: The investigators' team's long experience in this field permitted the identification of the interaction between light and MV (specifically riboflavin) that leads to doubling the amount of peroxides contaminating the PN. The complexity of complete photo-protection encountered by the team to conduct small uni-center studies and the incapacity to introduce the complete photo-protection in daily clinical practice led the team to create this simple intervention that will address the problem at its origin in a practical way. All trials, including complete PN photo-protection, faced the complexity of keeping MV away from light while needing to prepare the PN admixture under the light of a sterile hood. Added to this was the complexity of completely covering the PN bag while compounding the admixture. Light exposure may also occur during the transportation of the PN from the hospital pharmacy to the neonatal unit (even with special attention to the bottom of the bag and the area around the tubing being well covered). The proposed intervention will eliminate all these complex procedures by directly sampling the MV in a photo-protected syringe, transporting it in this syringe, and directly infusing the MV into the photo-protected intravenous lines through its infusion into the patient.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date January 17, 2022
Est. primary completion date October 27, 2021
Accepts healthy volunteers No
Gender All
Age group 1 Minute to 2 Days
Eligibility Inclusion Criteria: - Infants < 28 weeks of gestational age - Obtaining parental consent before the start of the first PN prescribed by the attending physician Exclusion Criteria: - Significant congenital malformations - Infant is currently enrolled in another trial -unless approval of trial research team- - Parent inability to comprehend and consent

Study Design


Intervention

Other:
Photo-protection
The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
Standard Care
This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.

Locations

Country Name City State
Canada CHU Sainte-Justine Montréal Quebec
Canada University of Montreal, Sainte-Justine Hospital Montréal

Sponsors (1)

Lead Sponsor Collaborator
St. Justine's Hospital

Country where clinical trial is conducted

Canada, 

References & Publications (11)

Bassiouny MR, Almarsafawy H, Abdel-Hady H, Nasef N, Hammad TA, Aly H. A randomized controlled trial on parenteral nutrition, oxidative stress, and chronic lung diseases in preterm infants. J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):363-9. — View Citation

Chessex P, Harrison A, Khashu M, Lavoie JC. In preterm neonates, is the risk of developing bronchopulmonary dysplasia influenced by the failure to protect total parenteral nutrition from exposure to ambient light? J Pediatr. 2007 Aug;151(2):213-4. — View Citation

Chessex P, Laborie S, Nasef N, Masse B, Lavoie JC. Shielding Parenteral Nutrition From Light Improves Survival Rate in Premature Infants. JPEN J Parenter Enteral Nutr. 2017 Mar;41(3):378-383. doi: 10.1177/0148607115606407. Epub 2016 Sep 30. Review. — View Citation

Elremaly W, Mohamed I, Mialet-Marty T, Rouleau T, Lavoie JC. Ascorbylperoxide from parenteral nutrition induces an increase of redox potential of glutathione and loss of alveoli in newborn guinea pig lungs. Redox Biol. 2014 May 20;2:725-31. doi: 10.1016/j.redox.2014.05.002. eCollection 2014. — View Citation

Laborie S, Lavoie JC, Chessex P. Increased urinary peroxides in newborn infants receiving parenteral nutrition exposed to light. J Pediatr. 2000 May;136(5):628-32. — View Citation

Laborie S, Lavoie JC, Pineault M, Chessex P. Contribution of multivitamins, air, and light in the generation of peroxides in adult and neonatal parenteral nutrition solutions. Ann Pharmacother. 2000 Apr;34(4):440-5. — View Citation

Lavoie JC, Rouleau T, Chessex P. Interaction between ascorbate and light-exposed riboflavin induces lung remodeling. J Pharmacol Exp Ther. 2004 Nov;311(2):634-9. Epub 2004 Jul 13. — View Citation

Mohamed I, Elremaly W, Rouleau T, Lavoie JC. Ascorbylperoxide Contaminating Parenteral Nutrition Is Associated With Bronchopulmonary Dysplasia or Death in Extremely Preterm Infants. JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):1023-1029. doi: 10.1177/0148607116643704. Epub 2016 Apr 1. — View Citation

Mohamed I, Elremaly W, Rouleau T, Lavoie JC. Oxygen and parenteral nutrition two main oxidants for extremely preterm infants: 'It all adds up'. J Neonatal Perinatal Med. 2015;8(3):189-97. doi: 10.3233/NPM-15814091. — View Citation

Saugstad OD. Oxygen and oxidative stress in bronchopulmonary dysplasia. J Perinat Med. 2010 Nov;38(6):571-7. doi: 10.1515/jpm.2010.108. Epub 2010 Aug 31. Review. — View Citation

Thibeault DW. The precarious antioxidant defenses of the preterm infant. Am J Perinatol. 2000;17(4):167-81. Review. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in urine peroxides concentration From each urine sample, an aliquot (0.2 ml) will be used for creatinin measurement whereas another (0.5 ml) will be used for peroxide determination using the ferrous oxidation/xylenol orange technique. H2O2 will serve for the standard curve. The results will be expressed as µmol equ H2O2/mg creatinine. Baseline, 48 hours post-parenteral nutrition and on day 7 of life
Secondary Urinary ascorbylperoxide (AscOOH) Urine AscOOH concentration will be determined using Mass spectrometry. On day 7 of life
Secondary Whole blood glutathione redox potential Whole blood levels of glutathione (GSH) and glutathione disulfide (GSSG) will be measured by capillary electrophoresis as previously described by the investigators' team, using 0.5 ml of blood. The whole blood redox potential (mV) will be calculated, using the Nernst equation. On day 7 of life
Secondary Whole blood glutathione redox potential Whole blood levels of glutathione (GSH) and glutathione disulfide (GSSG) will be measured by capillary electrophoresis as previously described by our team, using 0.5 ml of blood. The whole blood redox potential (mV) will be calculated, using the Nernst equation. At 36 weeks Post-Menstrual Age
Secondary Serum inflammatory cytokines: Interleukin 1 alpha (IL-1alpha) and beta (IL-1beta), Interleukin 6 (IL-6), Interleukin 8 (IL-8), Interleukin (IL-10), Tumor Necrosis Factor alpha (TNF-alpha), Vascular Endothelial Growth Factor (VEGF) Multiplex assay (Luminex R&D systems), using 0.1 ml of blood On day 7 of life
Secondary Serum inflammatory cytokines: IL-1alpha, IL-1beta, IL-6, IL-8, IL-10, TNF-alpha, VEGF Multiplex assay (Luminex R&D systems), using 0.1 ml of blood At 36 weeks Post-Menstrual Age
Secondary Clinical outcome - Incidence of Bronchopulmonary dysplasia (BPD) and BPD severity (Mild, moderate, sever) According to the National Institute of Child Health and Human Development (NICHD) criteria (Jobe Alan H.,2001) At 36 weeks Post-Menstrual Age
Secondary Clinical outcome - Mortality rate Death before 36 weeks post menstrual age At 36 weeks Post-Menstrual Age
Secondary Clinical outcome - length of mechanical ventilation (invasive, non-invasive) Total number of days on mechanical ventilation (both invasive and non invasive respiratory support) From birth to discharge home, an average of 4 months
Secondary Clinical outcome - length of supplemental oxygen (in days) Total number of days on Nasal cannula O2 supplements From birth to discharge home, an average of 4 months
Secondary Clinical outcome - Incidence and stage of necrotizing enterocolitis (According to Bell's classification) Necrotizing enterocolitis stages as defind by Bell stage II or higher. The incidence in the two arms will be reported and compared From birth to discharge home, an average of 4 months
Secondary Clinical outcome - Incidence and grade of intraventricular hemorrhage (IVH), according to Papille criteria Any intraventricular hemorrhage (IVH), IVH grade III and IV in each arm will be reported and compared. From birth to discharge home, an average of 4 months
Secondary Clinical outcome - Incidence of significant liver cholestasis (defined as two or more consecutive conjugated bilirubin values = 34 µmol/L) Cholestasis is defined as two or more consecutive conjugated bilirubin values = 34 µmol/L. The incidence of cholestasis in each arm will be reported and compared. From birth to discharge home, an average of 4 months
Secondary Clinical outcome - Incidence and stage of Retinopathy Of Prematurity (ROP) (highest stage) The incidence of ROP stage II and higher as defined by the National Eye Institute will be reported and compared. From birth to discharge home, an average of 4 months
Secondary Clinical outcome - Incidence of significant Patent Ductus Arteriosus (PDA) PDA requiring medical or surgical treatment according to the treating neonatologist will be reported and compared. From birth to discharge home, an average of 4 months
Secondary Clinical outcome - infant anthropometry: weight Weight in grams At 36 weeks Post-Menstrual Age
Secondary Clinical outcome - infant anthropometry: length Length in centimeters At 36 weeks Post-Menstrual Age
Secondary Clinical outcome - infant anthropometry: head circumference Head circumference in centimeters At 36 weeks Post-Menstrual Age
Secondary Clinical outcome - length of hospital stay (in days) Total number of days till discharge home From birth to discharge home, an average of 4 months
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT03682354 - ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Completed NCT00269256 - Stress, Environment, and Genetics in Urban Children With Asthma N/A
Terminated NCT00233207 - IC14 Antibodies to Treat Individuals With Acute Lung Injury Phase 2
Completed NCT00281216 - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Active, not recruiting NCT00115297 - Montelukast for Early Life Wheezing Phase 2/Phase 3
Completed NCT00094276 - Intervention for Improving Asthma Care for Minority Children in Head Start N/A
Completed NCT00091767 - Genetic Studies in Difficult to Treat Asthma: TENOR N/A
Completed NCT00089752 - Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea N/A
Completed NCT00069823 - Study of Acid Reflux in Asthma Phase 3
Completed NCT00083798 - Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland N/A